AMGN Q4 Deep Dive: Product Portfolio Expansion and Pipeline Progress Drive Outlook [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
The company's full-year revenue guidance of $37.7 billion at the midpoint came in 1.7% above analysts' estimates. Its non-GAAP profit of $5.29 per share was 11.9% above analysts' consensus estimates. Is now the time to buy AMGN? Find out in our full research report (it's free). Revenue: $9.87 billion vs analyst estimates of $9.47 billion (8.6% year-on-year growth, 4.1% beat) Adjusted EPS: $5.29 vs analyst estimates of $4.73 (11.9% beat) Adjusted Operating Income: $4.01 billion vs analyst estimates of $3.64 billion (40.6% margin, 10.1% beat) Adjusted EPS guidance for the upcoming financial year 2026 is $22.30 at the midpoint, beating analyst estimates by 0.9% Operating Margin: 27.6%, up from 25.4% in the same quarter last year Market Capitalization: $182.3 billion Amgen's fourth-quarter results reflected broad-based sales growth across its diverse portfolio, with management crediting strong volume gains in key products such as Repatha, Evenity, and Tezspire. CEO Robert
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Argus from $360.00 to $400.00. They now have a "buy" rating on the stock.MarketBeat
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Guggenheim from $305.00 to $347.00. They now have a "neutral" rating on the stock.MarketBeat
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $285.00 to $295.00. They now have a "hold" rating on the stock.MarketBeat
- CVS Health to swap Amgen and Lilly's bone drugs with biosimilars in commercial formularies [Seeking Alpha]Seeking Alpha
- Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline” [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/3/26 - Beat
AMGN
Sec Filings
- 2/3/26 - Form 8-K
- 1/30/26 - Form 8-K
- 11/21/25 - Form 4
- AMGN's page on the SEC website